Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14561
Abstract: Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is… read more here.
Keywords: vte; venous thromboembolism; cancer; extended treatment ... See more keywords
Low‐dose apixaban in extended treatment of cancer‐associated thrombosis: Less is more?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15685
Abstract: We read with great interest the paper by Larsen et al. 1 about low-dose apixaban in extended treatment of cancer- associated thrombosis (CAT) after 6 months of full- dose treatment. The optimal duration of anticoagulant… read more here.
Keywords: dose apixaban; apixaban extended; extended treatment; treatment ... See more keywords
Predictors of slow clinical response and extended treatment in patients with extra-pulmonary tuberculosis in Pakistan, A hospital-based prospective study
Sign Up to like & getrecommendations! Published in 2021 at "PLoS ONE"
DOI: 10.1371/journal.pone.0259801
Abstract: The optimal duration of treatment in different forms of extrapulmonary tuberculosis (EPTB) is not clearly defined. This study aimed to identify predictors of slow clinical response and extended anti-TB treatment in EPTB patients. Socio-demographic, clinical,… read more here.
Keywords: treatment; slow clinical; predictors slow; response extended ... See more keywords